Clinical Trials Browser

Phase 2 × OTHER × AZD 6244 × Clear all

NCT06188741 2026-03-12

NF114

Phase 2 Recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Phase 2 Not yet recruiting

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT03392246 2026-01-22

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02151084 2025-12-16

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

Phase 2 Active not recruiting

Gastrointestinal

Gallbladder Neoplasms, Recurrence

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03095248 2025-04-22

SEL-TH-1601

Phase 2 Terminated

10 enrolled 9 charts

Ependymoma, Glioma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms

NCT06763315 2025-01-08

LS-NF1PNs

Phase 2 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06620354 2024-10-01

Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule

Phase 2 Not yet recruiting

Neurofibromatosis 1

NCT06621082 2024-10-01

The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule

Phase 2 Not yet recruiting

Neurofibromatosis 1

NCT01256359 2024-08-15

DOC-MEK

Phase 2 Completed

83 enrolled 60 charts

Melanoma

NCT02393690 2024-07-26

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Phase 2 Completed

60 enrolled 12 charts

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT02117167 2024-01-10

SAFIR02_Lung

Phase 2 Completed

Non-small Cell Lung Cancer Metastatic

NCT03433183 2023-12-26

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Phase 2 Completed

Neurofibromatosis 1, Neurofibrosarcoma

NCT01248247 2022-01-12

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

334 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00780676 2020-09-03

Personalized Treatment Selection for Metastatic Breast Cancer

Phase 2 Terminated

97 enrolled 7 charts

Breast Neoplasms

NCT01160718 2019-05-15

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

Phase 2 Completed

Breast Neoplasms

NCT03004105 2018-03-16

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02685657 2016-02-22

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms